Our pipeline

OPM is the recognized leader in new generation small macrocyclic kinase inhibitors. Its Nanocyclix® platform gives access to highly potent and selective inhibitors for novel and intractable kinases. We develop new theranostic approaches capitalizing on the networks and the local ecosystem we have built over the last decade. Combined with artificial intelligence based patient data generation, we set the standard for the Precision Medicine of the future.